Vaxcyte Inc. Common Stock vs StandardAero Inc. Common Stock — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while StandardAero Inc. Common Stock trades at $19.73 (market cap $6.58B). The key difference: Vaxcyte Inc. Common Stock is the larger of the two by market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, StandardAero Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and StandardAero Inc. Common Stock for 0 Days on average.
| PCVX | SARO | |
|---|---|---|
Market Cap | $10.51B | $6.58B |
Volume | 2,644,694 | 3,663,186 |
Sector | Health | Industrials |
52-Week High | $73.82 | $33.12 |
52-Week Low | $40.32 | $19.76 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $9.14B | $8.96B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →StandardAero, Inc. is an independent provider of aircraft engine maintenance, repair, and overhaul services, supporting commercial, military, and business aviation customers across more than 40 engine platforms.
Read more on SARO →